Please visit ancan.org to learn more about our free, drop-in peer-led support groups
To sign up for a Reminder, go to ancan.org/cont...
----------------------------------------
On July 29, 2021, Drs. Ming Zhou, Pathologist-in-Chief and Chair of Anatomic and Clinical Pathology, Tufts Medical School, and Dr. Scott Eggener, Vice Chair of Urology at the University of Chicago, debated this question: Is Gleason 6 a cancer?
The doctors each presented their cases at the AnCan program in this video. Zhou took the view that if it looks like a cancer, which Gleason does under the microscope, then it’s a cancer. One of Eggener’s key points, in response, is that he has never seen a patient die from Gleason 6 so why call it a cancer.
The question-and-answer period covered such issues as whether a high-volume Gleason 6 is more risky than a low-volume Gleason 3+4=7. Eggener argued that these Gleason 6’s can be risky. He also said not enough men with 3+4 go in AS. The doctors engage in an informative and entertaining cross-fire discussion that should not be missed.
So who won?Our poll showed that before the debate that 55% of respondents thought Gleason 6 is a cancer with 10% thought it wasn’t a cancer. 35% were unsure.The numbers changed dramatically after the debate. Only 22% thought Gleason 6 is cancer. And 47% said Gleason 6 is not a cancer. 31% were unsure.Dr. Eggener clearly won the debate.
The following day, Dr. Zhou got back to us saying:
"Dr. Eggener has won me over. I am now in his camp. I just proposed to work together to educate pathologists on this topic. As you know, I am also the president of Genitourinary Pathology Society (GUPS, an international GU pathology society). I will do my part to change the name."
So if there's a real winner from this debate, it's that AnCan is bringing the sides closer together ...... !!
For more on the topic, read moderator Howard Wolinsky's MedPage Today (free subscription): www.medpagetod...